Paper Details

  1. Home
  2. Paper Details

Multicenter evaluation of azithromycin and cefaclor in acute lower respiratory tract infections.

Author: DarkD

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A 5-day course of once-daily azithromycin was as effective as a 10-day three times daily course of cefaclor in treating acute lower respiratory tract infections, with similar safety profiles.
Paper Details　
Original Abstract of the Article :
This was a randomized, third-party-blinded, multicenter study that compared once-daily azithromycin (500 mg on day 1, followed by 250 mg on days 2-5) to cefaclor (500 mg three times daily for 10 days) in the treatment of patients with acute bronchitis or pneumonia. A total of 546 patients were enter...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0002-9343(91)90399-i

データ提供：米国国立医学図書館（NLM）

Azithromycin vs. Cefaclor: A Battle of Antibiotics

The field of [infectious diseases] constantly seeks effective and safe antibiotics to combat bacterial infections. This multicenter study compares the effectiveness of azithromycin, a macrolide antibiotic, and cefaclor, a cephalosporin antibiotic, in treating acute lower respiratory tract infections. The authors conducted a randomized, blinded trial to evaluate the clinical and bacteriologic outcomes of these two antibiotics. Their findings demonstrate that a 5-day course of azithromycin is as effective as a 10-day course of cefaclor in treating acute bronchitis and pneumonia, with comparable safety profiles.

Azithromycin: A Shorter Course for Effective Treatment

This research suggests that azithromycin can be a more convenient and efficient treatment option for acute lower respiratory tract infections compared to cefaclor. The authors found that a shorter course of azithromycin achieved comparable clinical and bacteriologic outcomes to a longer course of cefaclor, highlighting the potential for shorter treatment regimens with azithromycin. This finding can improve patient compliance and reduce healthcare costs.

Navigating the Labyrinth of Antibiotic Therapy

This research underscores the importance of considering the duration of antibiotic therapy when treating bacterial infections. It emphasizes the need to use antibiotics judiciously and choose therapies that minimize the duration of treatment while achieving effective outcomes. We should strive to navigate the labyrinth of antibiotic therapy with a balanced approach, ensuring that we combat infections effectively while minimizing the potential for resistance.

Dr. Camel's Conclusion

This study is like finding a shortcut through the vast desert of antibiotic therapy. Azithromycin emerges as a potential oasis, offering a shorter and more efficient route to combat bacterial infections while maintaining effectiveness and safety. It's a reminder that we must continue to explore innovative approaches to antibiotic therapy, seeking solutions that are effective, convenient, and sustainable.

Date :
  1. Date Completed 1991-11-20
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

1656740

DOI: Digital Object Identifier

10.1016/0002-9343(91)90399-i

Related Literature

Article Analysis
・Side Effects of cefaclor
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.